36 research outputs found
Recommended from our members
Systematic Characterization of Component Failures for the DIII-D Tokamak
A fusion reactor will be a fairly complex system consisting of many components. All the components are required to work in order to produce a plasma and control it. Some of the components will be large, and for economic reasons there will not be spares for all components. It is therefore important to have a system whereby troubles are communicated, recorded and analyzed. Such a trouble report system has been in place at the DIII-D tokamak facility for many years. The purpose of the system is to easily facilitate communication between the people that discover problems and those that fix the problems. The trouble sheets are logged into a computer database that is used to characterize the kind of problems that the facility experiences, and determine which equipment, software, or human errors are causing significant downtime. The information is also used to evaluate whether sufficient maintenance is done to the equipment and to provide a basis for replacing it. The original system was based on paper forms. About a year ago the system was changed to a web-based system. In the new system a trouble report is filled out using a web browser, and the information is emailed to the repair personnel and managers as soon as the form is submitted through the web. The paper will discuss the problems experienced at the DIII-D facility, and how the information is used to adjust the preventive maintenance schedule
Composition and structure of the RuO2(110) surface in an O2 and CO environment: implications for the catalytic formation of CO2
The phase diagram of surface structures for the model catalyst RuO2(110) in
contact with a gas environment of O2 and CO is calculated by density-functional
theory and atomistic thermodynamics. Adsorption of the reactants is found to
depend crucially on temperature and partial pressures in the gas phase.
Assuming that a catalyst surface under steady-state operation conditions is
close to a constrained thermodynamic equilibrium, we are able to rationalize a
number of experimental findings on the CO oxidation over RuO2(110). We also
calculated reaction pathways and energy barriers. Based on the various results
the importance of phase coexistence conditions is emphasized as these will lead
to an enhanced dynamics at the catalyst surface. Such conditions may actuate an
additional, kinetically controlled reaction mechanism on RuO2(110).Comment: 12 pages including 8 figure files. Submitted to Phys. Rev. B. Related
publications can be found at http://www.fhi-berlin.mpg.de/th/paper.htm
Searches for lepton-flavour-violating decays of the Higgs boson in TeV collisions with the ATLAS detector
This Letter presents direct searches for lepton flavour violation in Higgs boson decays, H â eÏ and
H â ÎŒÏ , performed with the ATLAS detector at the LHC. The searches are based on a data sample
of protonâproton collisions at a centre-of-mass energy âs = 13 TeV, corresponding to an integrated
luminosity of 36.1 fbâ1. No significant excess is observed above the expected background from Standard
Model processes. The observed (median expected) 95% confidence-level upper limits on the leptonflavour-violating branching ratios are 0.47% (0.34+0.13â0.10%) and 0.28% (0.37+0.14â0.10%) for H â eÏ and H â ÎŒÏ , respectively.publishedVersio
Search for flavour-changing neutral currents in processes with one top quark and a photon using 81 fbâ»Âč of pp collisions at \sqrts = 13 TeV with the ATLAS experiment
A search for flavour-changing neutral current (FCNC) events via the coupling of a top quark, a photon, and an up or charm quark is presented using 81 fbâ1 of protonâproton collision data taken at a centre-of-mass energy of 13 TeV with the ATLAS detector at the LHC. Events with a photon, an electron or muon, a b-tagged jet, and missing transverse momentum are selected. A neural network based on kinematic variables differentiates between events from signal and background processes. The data are consistent with the background-only hypothesis, and limits are set on the strength of the tqÎł coupling in an effective field theory. These are also interpreted as 95% CL upper limits on the cross section for FCNC tÎł production via a left-handed (right-handed) tuÎł coupling of 36 fb (78 fb) and on the branching ratio for tâÎłu of 2.8Ă10â5 (6.1Ă10â5). In addition, they are interpreted as 95% CL upper limits on the cross section for FCNC tÎł production via a left-handed (right-handed) tcÎł coupling of 40 fb (33 fb) and on the branching ratio for tâÎłc of 22Ă10â5 (18Ă10â5). © 2019 The Author(s
Measurement of the inclusive cross-section for the production of jets in association with a Z boson in protonâproton collisions at 8 TeV using the ATLAS detector
Abstract: The inclusive cross-section for jet production in association with a Z boson decaying into an electronâpositron pair is measured as a function of the transverse momentum and the absolute rapidity of jets using 19.9 fb-1 of s=8 TeV protonâproton collision data collected with the ATLAS detector at the Large Hadron Collider. The measured Z+ jets cross-section is unfolded to the particle level. The cross-section is compared with state-of-the-art Standard Model calculations, including the next-to-leading-order and next-to-next-to-leading-order perturbative QCD calculations, corrected for non-perturbative and QED radiation effects. The results of the measurements cover final-state jets with transverse momenta up to 1 TeV, and show good agreement with fixed-order calculations
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Funding Information: Funding The study was funded by NORDFORSK (grant agreement no. 90825, project NORA), the Swedish Research Council (2018-02803), the Swedish innovation Agency (Vinnova), Innovationsfonden and The Research Council of Norway, Region Stockholm-Karolinska Institutet and Region VĂ€sterbotten (ALF), the Danish Rheumatism Association (R194-A6956), the Swedish Brain Foundation, Nils and Bibbi Jensens Foundation, the Knut and Alice Wallenberg Foundation, Margaretha af Ugglas Foundation, the South-Eastern Heath Region of Norway, the Health Research Fund of Central Denmark Region, Region of Southern Denmark, the A.P. Moller Foundation for the Advancement of Medical Science, the Colitis-Crohn Foreningen, the Novo Nordisk Foundation (NNF15OC0016932), Aase og Ejnar Danielsens Fond, Beckett-Fonden, Augustinus Fonden, Knud and Edith Eriksens Mindefond, Laege Sofus Carl Emil Friis and Hustru Olga Doris Friisâ Legat, the Psoriasis Forskningsfonden, the University of Aarhus, the Danish Rheumatism Association (R194-A6956, A1923, A3037 and A3570 â www. gigtforeningen.dk), Region of Southern Denmarkâs PhD Fund, 12/7725 (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital. dk). MoBa Genetics has been funded by the Research Council of Norway (#229624, #223273), South East and Western Norway Health Authorities, ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Novo Nordisk Foundation and the University of Bergen. KB and SB acknowledge the Novo Nordisk Foundation (grant NNF14CC0001). Funding Information: competing financial interests as employees. OAA is a consultant to HealthLytix. The following coauthors report the following but unrelated to the current report: Karolinska Institutet, with JA as principal investigator, has entered into agreements with the following entities, mainly but not exclusively for safety monitoring of rheumatology immunomodulators: Abbvie, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis and Sanofi, unrelated to the present study. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board memberships in Proscion A/S and Intomics A/S. BG has received research grants from AbbVie, Bristol Myers-Squibb and Pfizer; OH has received research grants from AbbVie, Novartis and Pfizer, DVJ has received speaker and consultation fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, AGL has received speaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; and CT has received consulting fees from Roche, speaker fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Publisher Copyright: © Funding Information: Funding The study was funded by NORDFORSK (grant agreement no. 90825, project NORA), the Swedish Research Council (2018-02803), the Swedish innovation Agency (Vinnova), Innovationsfonden and The Research Council of Norway, Region Stockholm-Karolinska Institutet and Region VĂ€sterbotten (ALF), the Danish Rheumatism Association (R194-A6956), the Swedish Brain Foundation, Nils and Bibbi Jensens Foundation, the Knut and Alice Wallenberg Foundation, Margaretha af Ugglas Foundation, the South-Eastern Heath Region of Norway, the Health Research Fund of Central Denmark Region, Region of Southern Denmark, the A.P. Moller Foundation for the Advancement of Medical Science, the Colitis-Crohn Foreningen, the Novo Nordisk Foundation (NNF15OC0016932), Aase og Ejnar Danielsens Fond, Beckett-Fonden, Augustinus Fonden, Knud and Edith Eriksens Mindefond, Laege Sofus Carl Emil Friis and Hustru Olga Doris Friisâ Legat, the Psoriasis Forskningsfonden, the University of Aarhus, the Danish Rheumatism Association (R194-A6956, A1923, A3037 and A3570 â www. gigtforeningen.dk), Region of Southern Denmarkâs PhD Fund, 12/7725 (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital. dk). MoBa Genetics has been funded by the Research Council of Norway (#229624, #223273), South East and Western Norway Health Authorities, ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Novo Nordisk Foundation and the University of Bergen. KB and SB acknowledge the Novo Nordisk Foundation (grant NNF14CC0001). Funding Information: competing financial interests as employees. OAA is a consultant to HealthLytix. The following coauthors report the following but unrelated to the current report: Karolinska Institutet, with JA as principal investigator, has entered into agreements with the following entities, mainly but not exclusively for safety monitoring of rheumatology immunomodulators: Abbvie, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis and Sanofi, unrelated to the present study. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board memberships in Proscion A/S and Intomics A/S. BG has received research grants from AbbVie, Bristol Myers-Squibb and Pfizer; OH has received research grants from AbbVie, Novartis and Pfizer, DVJ has received speaker and consultation fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, AGL has received speaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; and CT has received consulting fees from Roche, speaker fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Publisher Copyright: ©Objectives To find causal genes for rheumatoid arthritis (RA) and its seropositive (RF and/or ACPA positive) and seronegative subsets. Methods We performed a genome-wide association study (GWAS) of 31 313 RA cases (68% seropositive) and âŒ1 million controls from Northwestern Europe. We searched for causal genes outside the HLA-locus through effect on coding, mRNA expression in several tissues and/or levels of plasma proteins (SomaScan) and did network analysis (Qiagen). Results We found 25 sequence variants for RA overall, 33 for seropositive and 2 for seronegative RA, altogether 37 sequence variants at 34 non-HLA loci, of which 15 are novel. Genomic, transcriptomic and proteomic analysis of these yielded 25 causal genes in seropositive RA and additional two overall. Most encode proteins in the network of interferon-Alpha/beta and IL-12/23 that signal through the JAK/STAT-pathway. Highlighting those with largest effect on seropositive RA, a rare missense variant in STAT4 (rs140675301-A) that is independent of reported non-coding STAT4-variants, increases the risk of seropositive RA 2.27-fold (p=2.1Ă10-9), more than the rs2476601-A missense variant in PTPN22 (OR=1.59, p=1.3Ă10-160). STAT4 rs140675301-A replaces hydrophilic glutamic acid with hydrophobic valine (Glu128Val) in a conserved, surface-exposed loop. A stop-mutation (rs76428106-C) in FLT3 increases seropositive RA risk (OR=1.35, p=6.6Ă10-11). Independent missense variants in TYK2 (rs34536443-C, rs12720356-C, rs35018800-A, latter two novel) associate with decreased risk of seropositive RA (ORs=0.63-0.87, p=10-9-10-27) and decreased plasma levels of interferon-Alpha/beta receptor 1 that signals through TYK2/JAK1/STAT4. Conclusion Sequence variants pointing to causal genes in the JAK/STAT pathway have largest effect on seropositive RA, while associations with seronegative RA remain scarce.Peer reviewe
Recommended from our members
Recent results from the DIII-D tokamak
The DIII-D national fusion research program focuses on establishing the scientific basis for optimization of the tokamak approach to fusion energy production. The symbiotic development of research, theory, and hardware continues to fuel the success of the DIII-D program. During the last year, a radiative divertor and a second cryopump were installed in the DIII-D vacuum vessel, an array of central and boundary diagnostics were added, and more sophisticated computer models were developed. These new tools have led to substantial progress in the understanding of the plasma. The authors now have a better understanding of the divertor as a means to manage the heat, particle, and impurity transport pumping of the plasma edge using the in situ divertor cryopumps effectively controls the plasma density. The evolution of diagnostics that probe the interior of the plasma, particularly the motional Stark effect diagnostic, has led to a better understanding of the core of the plasma. This understanding, together with tools to control the profiles, including electron cyclotron waves, pellet injection, and neutral beam injection, has allowed them to progress in making plasma configurations that give rise to both low energy transport and improved stability. Most significant here is the use of transport barriers to improve ion confinement to neoclassical values. Commissioning of the first high power (890 kW) 110 GHz gyrotron validates an important tool for managing the plasma current profile, key to maintaining the transport barriers. An upgraded plasma control system, ``isoflux control,`` which exploits real time MHD equilibrium calculations to determine magnetic flux at specified locations within the tokamak vessel and provides the means for precisely controlling the plasma shape and, in conjunction with other heating and fueling systems, internal profiles